Labcorp Drug Development has continued to invest in the technology, innovation and expertise globally to support clients focused on bringing life-changing treatments to patients with neurological diseases. We recently spoke with Robert Martone, Associate Director, Neurology Biomarkers with the Biomarker Solution Center, to learn about the acceleration and expansion of …
Biomarker Q&A: The power of precision medicine for kidney disease
Labcorp Drug Development has continued to invest in the technology, capacity and expertise globally to support the evolving and complex analytical needs of our clients. We recently spoke with Katherine T Landschulz, PhD, Sr. Director and Lead Scientist, Cardiovascular and Metabolic Disease, Neurodegeneration at Labcorp Drug Development, to learn about …
Cell & Gene Therapy Answers: The Evolving Cell & Gene Therapy Landscape
Your source for answers to the complex challenges of cell and gene therapy development. We recently sat down with Maryland Franklin, Vice President and Enterprise Head of Cell & Gene Therapy at Labcorp Drug Development, to discuss key considerations for developing cell or gene therapies in today’s quickly expanding pipeline.
Using data visualization tools on SEND datasets: a graph is worth a thousand data points
SEND [Standard for Exchange of Nonclinical Data] is more than just a tool to facilitate nonclinical data submissions to the FDA. SEND datasets are rich in information, albeit in a form that’s time-consuming for non-experts to parse. With the right visualization tools, SEND data sets can inform nonclinical programs and …
Exploring new opportunities for biomarkers in immuno-oncology
Pharmaceutical companies are increasingly relying on biomarkers to deliver precision medicine in immuno-oncology. Biomarkers can accelerate drug development and reduce the overall cost; they also allow sponsors to identify failed treatments sooner so that resources are not wasted on expensive, late-stage trials with unsafe or inactive compounds. Finally, these tests …
Can We Expand Companion Diagnostics Beyond Oncology?
The majority of today’s approved companion (and complementary) diagnostics (CDx) support personalized medicine efforts in oncology, a testament to researchers’ growing knowledge regarding the genetic pathways impacted in various cancers. That understanding increases our ability to convert such knowledge of biology into treatments that specifically target disease based on a …